StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM)

Equities researchers at StockNews.com started coverage on shares of CEL-SCI (NYSE:CVM) in a report issued on Friday. The brokerage set a “sell” rating on the stock.

CEL-SCI Stock Performance

NYSE CVM opened at $0.26 on Friday. The company’s 50 day moving average is $0.37 and its 200-day moving average is $0.65. CEL-SCI has a 12-month low of $0.25 and a 12-month high of $2.39. The company has a quick ratio of 1.09, a current ratio of 1.07 and a debt-to-equity ratio of 0.66. The firm has a market cap of $20.08 million, a P/E ratio of -0.54 and a beta of 0.67.

Institutional Trading of CEL-SCI

Several hedge funds and other institutional investors have recently modified their holdings of CVM. Plotkin Financial Advisors LLC bought a new stake in shares of CEL-SCI in the third quarter valued at approximately $98,000. Geode Capital Management LLC raised its position in shares of CEL-SCI by 9.6% in the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after purchasing an additional 53,879 shares during the period. Finally, Thoroughbred Financial Services LLC raised its position in shares of CEL-SCI by 40.1% in the fourth quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock valued at $76,000 after purchasing an additional 54,900 shares during the period. Institutional investors own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.